Flap adhesion and effect on postoperative complication rates using Tissuglu® in mastectomy patients

Christian Eichler · Petra Fischer · Axel Sauerwald · Faten Dahdouh · Mathias Warm

Received: 29 December 2014 / Accepted: 23 January 2015 / Published online: 10 February 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract
Introduction Post-mastectomy seroma and related complications are common problems in modern oncological surgery. Occurrence rates of up to 59 % have been reported in literature. High-risk patients, that is, those who have undergone previous surgeries, present with a high body mass index, have had radiation or chemotherapy, present a particular challenge. Noninvasive measures such as fibrin-based sealants have thus far not been able to effectively reduce complications associated with fluid accumulation. A recent study using a lysine-derived urethane adhesive named TissuGlu® however, showed promising results in patients after abdominoplasty.

Methods 32 consecutively recruited patients received a mastectomy using a gold standard mastectomy technique as well as TissuGlu® flap fixation. A control group of 173 patients, having received a gold standard mastectomy-only, was analyzed retrospectively, totaling 205 patients. Primary endpoints were post-discharge seroma formation and revision surgery/re-hospitalization. Secondary endpoints were initial seroma volume, postoperative pain, hematoma formation and day of drain removal.

Results No significant difference in seroma formation was demonstrated. The revision surgery/re-hospitalization rate was reduced from 6.9 to 0 %, though this did not reach significance. Significant improvement could be shown in the TissuGlu® group regarding time to drain removal (17 % decrease), and hematoma formation (14 % decrease). No difference was shown in postoperative pain.

Conclusion Although patient numbers are still small, advantages in revision surgery/re-hospitalization rate, hematoma formation as well as time to drain removal was shown for the TissuGlu® group.

Clinical question/level of evidence Therapeutic, IV.

Keywords Breast cancer · Mastectomy · Seroma · Prevention · TissuGlu · Drain · Time to drain removal

Introduction

Post-mastectomy seroma and its associated complications remain problematic in modern oncological surgery [1, 2]. The most common approach for preventing seroma is the placement of surgical drains within the wound area, though the efficacy of this approach is not universally acknowledged and the problem persists in spite of the use of drains [1]. Other approaches have been evaluated to reduce the
incidence of complications associated with seroma forma-
tion, but a consensus on the best solution remains elusive.
Recent studies aimed at the reduction or elimination of
dead space have shown some promise in reducing these
complications in other surgical techniques. Two options
include the use of progressive tension or quilting suture
techniques and the less invasive application of a lysine-
derived urethane adhesive (TissuGlu®, Cohera Medical,
Pittsburgh, PA, USA) [3–7]. Our group already demon-
strated the use of TissuGlu® in the successful resolution of
a persistent post-mastectomy seroma [8]. While a plethora
of literature is available on the benefits of post-surgical
adhesive is added. However, this method should be tested against the surgical gold
standard, which is a mastectomy with drain placement.
Risk factors such as radiation treatment, chemotherapy,
smoking habits, increased age and obesity are described in
literature [4, 5, 10–12] and are outside of the control of the
treating physician. Eliminating dead space in the wound
area may, however, be successfully achieved by the sur-
geon. An interesting question is thus to evaluate if mas-
tectomies performed using a surgical gold standard,
including a suction drain, may yield better results when this
adhesive is added.

Patients and methods

A total of 205 breast cancer patients were analyzed in this
study. For patients who received a bilateral mastectomy,
both sides were evaluated individually. This was the case
once in the TissuGlu® group and seven times in the control
group. 173 data sets were investigated retrospectively with
regard to age, smoking habits, body mass index (BMI) as
well as prior chemotherapy or previous radiation treatment.
The specific oncological character of each patient will not
be listed in this analysis since histology, grading, staging,
hormone receptor status, etc., does not impact surgical
outcome [13]. The decision to perform unilateral or bilat-
eral mastectomy was always derived from a tumor board.
Thus, gold standards in tumor therapy were adhered to. All
data were collected at the breast cancer center of the Mu-
nicipal Hospital Holweide, Cologne, Germany between
2010 until 2013. The TissuGlu® group consisted of con-
secutively enrolled patients in the year 2013. Primary
endpoints were postoperative complication rates, i.e.
seroma formation and severe adverse events. The latter was
considered to have occurred if either re-hospitalization
within 6-month post-surgery became necessary due to
wound healing complications (e.g. infection, deep he-
matoma, wound dehiscence) or in the case of persistent
seroma requiring treatment. Secondary endpoints were
post-surgical superficial hematoma, day of drain removal,
postoperative pain as well as total volume drained.

Surgery and post-surgical management

Naturally, several surgical approaches were available.
Mastectomies were performed with or without axillary
lymph node dissection, possibly in sentinel technique.
Drain placement is common practice in either situation. If
patients received an axillary lymph node dissection along
with a mastectomy, drains would be placed in both areas.
Analysis of the seroma formation focused on the mastec-
tomy area only. All surgeries were performed by the same,
experienced surgical team. The surgical procedure was also
the same for both groups, although the surgical adhesive
was added in the TG group. Figure 1 shows the TissuGlu®
application. Equal adhesive droplet placement is ensured
using an adhesive applicator. Following wound closure, the
surface is compressed and immobilized. Compression was
applied by an elastic bandage, wrapped around the thorax,
which was removed after 24 h. The compression regime
was the same for all mastectomy patients. Drains were
placed in all surgical sites, volume drained was recorded
and drains were removed when less than 30 ml/24 h fluid
was recorded, with the exception of the first postoperative
day. Drains remained in place for at least 24 h as standard
in-house protocols demanded. All drains were non-suction
drains.

Post-surgical follow-up for the TG group included reg-
ular clinician wound inspection and an additional pre-dis-
charge inspection as well as a 14-day follow-up. Seroma
formation after drain removal was detected using ultra-
sound and palpation. A bias in favor of the control group
had to be accepted, since only clinically relevant seroma,
(i.e. painful, infected, etc., was recorded for these patients,
as they would only revisit our hospital when such problems
occurred. Regular 14-day follow-up was provided in the
control group through their family practitioners. The TG
group, on the other hand, was more closely monitored;
seroma formation was recorded even if not clinically
relevant. To answer the central question of this paper as
conservatively as possible, we accepted this bias towards
the control group so as to not skew results in favor of the
TissuGlu® approach.

Informed consent

Written informed consent was obtained from all patients
for publication of this manuscript. A copy of the written
consent is available for review by the Editor-in-Chief of this journal. This study was conducted in accordance with institutional review board standard operating procedures.

Statistics

Statistical analysis was performed using the Vassar Stats® (Vassar College, Poughkeepsie, NY, USA) statistics program. Pearson’s Chi squared tests and \( t \) tests were used to evaluate significances when appropriate.

Results

Patient age was similar in both groups. The control group had a patient age of 62 (±14) years while the consecutively recruited TissuGlu® group had an average age of 67 (±13) years (\( p > 0.05 \)). Table 1 shows a summary of all results. BMI, prior chemotherapy and prior radiation treatment did not differ significantly. The average BMI was 27 (±7) and 26 (±7) in the control and TG, respectively. Prior radiation therapy was received by approximately 17 % of the control group patients, and 16 % of the TG group. Smoking habits differed significantly in favor of the TG group, where none of the patients listed a smoking habit, in comparison to the control group where approximately 14 % smokers were included. With exception of smoking habits, adequate comparability is thus given.

Primary endpoint results showed that approximately 16 % of the control group and 28 % of the TG group developed a postoperative seroma; this difference not being significant (\( p > 0.05 \)). The clinical relevance of this fluid accumulation should, however, be questioned since 7 % of the control group patients required revision surgeries or re-hospitalization and i.v. antibiotic treatment (3 cases) due to infection, whereas none of the TissuGlu® patients required re-hospitalization at all.

The secondary endpoints showed that superficial postoperative hematoma presented in 17 % of the control group versus 3 % in the TG group (\( p < 0.05 \)). No difference was shown in postoperative pain. Time to drain removal also differed significantly in favor of the TG group with 4.2 (±1.8) control groups vs. 3.5 (±1.5) TG days (\( p < 0.05 \)). The mean total amount of fluid collected per patient was also lower the TG group, although no statistical significance could be established here. Table 2 shows a subgroup analysis. Inter-group comparability is given. Distributions do not vary significantly for mastectomy-only, mastectomy plus SNL biopsy and mastectomy plus complete axillary dissection subsets. Results show adverse events to be evenly distributed within the control group. No adverse events are found in the TG group. Seroma formation occurs with the same frequency in mastectomy-only (48 %) and mastectomy-plus axillary dissection (44 %) subsets within the control group. This is not the case in the TG group. Here, 88 % of post-surgical seroma is found in the mastectomy group. The difference in distribution is most likely due to small sample size.
Discussion

Study group homogeneity needs to be established before comparing the two study arms. As patient groups do not differ in the age, previous radiation and chemotherapy nor BMI [14], comparison is possible. This was paramount as these are the most common risk factors for developing seroma or wound healing complication [4, 5, 9–11]. Smoking habits favored the TG group and future patient recruitment will have to take this fact into account. Only 3 of the 12 patients with an adverse event in the control group were smokers.

Primary endpoints

One of the primary endpoints seems to favor the control group, since approximately 16% of the control group developed a post-hospital discharge follow-up seroma vs. 28% of the TissuGlu® group (p > 0.05). As these results do not differ significantly, no definite conclusion may be drawn at this point. Nonetheless, it is important to discuss this issue. We may have to accept the possibility that the use of TG may lead to an increase in postsurgical seroma. This has not been shown or reported in previous literature and should be investigated in future trials with larger numbers. In addition, a bias in favor of the control group had to be accepted due to the retrospective nature of the control group analysis. As mentioned above, patients of the control group did not participate in mandatory follow-up visits in our in-house standard of care. Only clinically relevant seroma, i.e. patients presenting with pain, discomfort, etc., was recorded, as these patients returned seeking intervention. Clinically non-relevant seroma, i.e. patients presenting with pain, discomfort, etc., was not documented. Since post-surgical follow-up of the TG groups included several clinical inspections as well as ultrasound analysis of the immediate post-drain removal situation, non-clinically relevant seroma formation was in turn documented in this group. While a comparison between the two groups

Table 1

|                      | Control Total | Control % | TissuGlu® Total | TissuGlu® % | p value |
|----------------------|---------------|-----------|-----------------|-------------|---------|
| n                    | 173           | 32        | 62 (±14)        | 67 (±13)    | 0.094   |
| Age (years)          |               |           | 27 (±7)         | 26 (±7)     | 0.889   |
| Previous chemotherapy| 44            | 25.4      | 4               | 12.5        | 0.174   |
| Radiation            | 30            | 17.3      | 5               | 15.6        | 0.807   |
| Nicotine             | 24            | 13.9      | 0               | 0.007       |         |
| BMI                  | 27 (±7)       | 26 (±7)   | 4               | 12.5        | 0.174   |
| Superficial          | 29            | 16.8      | 1               | 3.1         | 0.045   |
| Post-surgical pain   | 1.5 (±1)      | 2.7 (±0.8)| 0.787           |             |         |
| Total volume         | 191 (±160)    | 152 (±116)| 0.08            |             |         |
| Follow-up seroma     | 27            | 15.6      | 8               | 27.6        | 0.06    |
| Adverse events       | 12            | 6.9       | 0               | 0.001       |         |

Table 2

|                      | Distribution (% of total) | Adverse event (% of total) | Seroma (% of total) |
|----------------------|---------------------------|----------------------------|---------------------|
| Control              | Mastectomy 63 (36 %)      | 5 (38 %)                   | 13 (48 %)           |
|                      | Axilla 79 (46 %)          | 4 (31 %)                   | 12 (44 %)           |
|                      | SNL 31 (18 %)             | 4 (31 %)                   | 2 (7 %)             |
|                      | Total 173                | 13                        | 27                  |
| TissuGlu®            | Mastectomy 14 (44 %)      | –                          | 7 (88 %)            |
|                      | Axilla 11 (34 %)          | –                          | –                   |
|                      | SNL 7 (22 %)              | –                          | 1 (13 %)            |
|                      | Total 32                 | –                          | 8                   |
|                      | p 0.223                  |                            | >0.001              |
may nonetheless be drawn, this issue will be addressed in a follow-up head-to-head prospective study.

Seven percent ($n = 12$) of the control group experienced a severe adverse event as defined above, and 0% of the TissuGlu® showed such complications. This supports the hypothesis above that seroma documented in the TG group for the primary endpoint may have been clinically non-relevant. Unfortunately, a significance level could not be achieved due to small sample number ($p > 0.05$).

Secondary endpoints

A recent study investigating a new 50 ml/24 h fluid production limit as an indicator for drain removal has demonstrated this volume to be an adequate and safe parameter for drain removal [15]. Our study used a limit of 30 ml/24 h which may be viewed as a more challenging approach to secondary endpoint analysis. Overall, patient satisfaction (subjectively) was high in the TissuGlu® group due to earlier drain removal: 3.5 days TG versus 4.2 days in the control group ($p < 0.05$). This represents a significant decrease in time to drain removal by 17%. Although the relevance of this may be theoretical in nature, the simple fact remains that drains may be removed earlier without increasing postoperative complication rates. Although patient satisfaction could not be retrospectively quantified, drain removal almost always results in a decrease in local discomfort, which in turn increases patient satisfaction. Future analyses will, therefore, attempt to quantify this aspect. Nonetheless, we are presented with an option for earlier drain removal when using TG, without significantly increasing the post-surgical complication rates [15–17].

Interestingly, post-surgical hematoma was significantly lower in the TissuGlu® group (3%) in comparison to the control group (29%) ($p < 0.05$). This issue will also have to be addressed in a future prospective study since no hemostatic properties of TissuGlu® are known. Since postoperative care was the same, with the exception of the follow-up visits, this phenomenon could not be explained. One may, however, speculate that by effectively eliminating dead space, surface to surface abrasion may be minimized.

**Conclusion**

This analysis shows that introducing TissuGlu® into a mastectomy area is a useful tool for improving overall surgical outcome. Non-inferiority could be shown for both primary endpoints. Follow-up seroma formation and postoperative adverse events did not differ significantly. A strong trend towards lower postoperative complication rates in the TissuGlu group was shown. Secondary endpoints showed significant improvement in the TissuGlu® group with a 17% decrease in time to drain removal as well as a 14% decrease in postoperative hematoma formation.

**Conflict of interest** None declared.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Hensel JM, et al. An outcomes analysis and satisfaction survey of 199 consecutive abdominoplasties. Ann Plast Surg. 2001;46(4): 357–63.
2. Boostrom SY, et al. Incidence of clinically significant seroma after breast and axillary surgery. J Am Coll Surg. 2009;208(1): 148–50.
3. Weinrauch JC, et al. Preventing seroma in the latissimus dorsi flap donor site with fibrin sealant. Ann Plast Surg. 2004;53(1):12–6.
4. Pollock, H, Pollock T. Progressive tension sutures: a technique to reduce local complications in abdominoplasty. Plast Reconstr Surg. 2000;105(7):2583–6 (discussion 2587–8).
5. Pollock TA, Pollock H. No-drain abdominoplasty with progressive tension sutures. Clin Plast Surg. 2010;37(3):515–24.
6. Gilbert TW, et al. Prevention of seroma formation with TissuGlu(R) surgical adhesive in a canine abdominoplasty model: long term clinical and histologic studies. J Plast Reconstr Aesthet Surg. 2013;66(3):414–22.
7. Paepke S, Kiechle M. Selective tissue adhesion reducing seroma formation in extensive breast surgery: The application of TissuGlu®—only problematic case solver or possible standard procedure? Eur J Surg Oncol. 2013;39(5):496.
8. Eichler C, et al. Seroma suppression using TissuGlu(R) in a high-risk patient post-mastectomy: a case report. J Med Case Rep. 2013;7(1):138.
9. Puttawibul P, et al. Mastectomy without drain at pectoral area: a randomized controlled trial. J Med Assoc Thai. 2003;86(4): 325–31.
10. Shestak KC. Progressive tension sutures: a technique to reduce local complications in abdominoplasty. Plast Reconstr Surg. 2000;105(7):2587–8.
11. Walgenbach KJ, et al. Randomized, prospective study of TissuGlu(R) surgical adhesive in the management of wound drainage following abdominoplasty. Aesthet Plast Surg. 2012;36(3):491–6.
12. Seenivasagam Kottayasamy, Gupta RV, Singh G. Prevention of seroma formation after axillary dissection-a comparative randomized clinical trial of three methods. Breast J. 2013;19(5): 478–84.
13. Srivastava V, Basu S, Shukla VK. Seroma formation after breast cancer surgery: what we have learned in the last two decades. J Breast Cancer. 2012;15(4):373–80.
14. Zielinski J, et al. Analysis of selected factors influencing seroma formation in breast cancer patients undergoing mastectomy. Arch Med Sci. 2013;9(1):86–92.
15. Okada, N, et al. Early removal of drains and the incidence of seroma after breast surgery. Breast Cancer. 2013;22:79–83.
16. Okada N, et al. Early removal of drains and the incidence of seroma after breast surgery. Breast Cancer. 2015;22(1):79–83.
17. Kuroi K, et al. Effect of mechanical closure of dead space on seroma formation after breast surgery. Breast Cancer. 2006;13(3): 260–5.